These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy. Evans DB; George B; Tsai S Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369 [No Abstract] [Full Text] [Related]
4. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. Polish A; Joseph NE; Marsh RW Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer? Kelly KN; Macedo FI; Merchant NB Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439 [No Abstract] [Full Text] [Related]
6. Neoadjuvant therapy for resectable pancreatic cancer. Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939 [TBL] [Abstract][Full Text] [Related]
7. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? Reni M World J Gastroenterol; 2010 Oct; 16(39):4883-7. PubMed ID: 20954273 [TBL] [Abstract][Full Text] [Related]
9. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? Hackert T; Ulrich A; Büchler MW Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331 [No Abstract] [Full Text] [Related]
12. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P Oncology; 2015; 89(1):37-46. PubMed ID: 25766660 [TBL] [Abstract][Full Text] [Related]
13. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642 [TBL] [Abstract][Full Text] [Related]
14. Role of surgery in pancreatic cancer. Buanes TA World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216 [TBL] [Abstract][Full Text] [Related]
15. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658 [TBL] [Abstract][Full Text] [Related]